OSLO, NORWAY - February 19, 2026: Genetic Analysis AS ("GA" or "the Company") announces that its patent application US2017/0369941 has been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent, entitled "METHOD FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP'S", strengthens the protection of GA's proprietary diagnostic technology. GA maintains an active patent strategy covering all major geographical markets and has previously announced approval in the EU and other countries for this patent.
CEO Ronny Hermansen comments:
"High analytical accuracy is fundamental in molecular diagnostics. This patent protects technology that reduces the risk of false-positive signals, thereby increasing the reliability of our assays. Securing protection in the U.S. strengthens our technological position in a key market and supports our long-term commercial strategy."
The patent covers a technology that enhances the accuracy of molecular diagnostic assays by minimizing false-positive signals in systems based on DNA polymerases, ddNTPs, and fluorophores.
It addresses a source of error in DNA-based tests used to detect specific genetic sequences. The inventors showed that some reagents in these assays, and sometimes the enzyme used in the reaction, can bind to DNA in unintended ways and produce misleading signals. The invention describes practical steps to reduce these effects, such as removing or inactivating the enzyme at certain stages, adjusting reaction conditions, or redesigning the DNA components so that only the intended binding events occur. By doing this, the tests yield more accurate and more reliable results.
The patent has been approved for grant by United States Patent and Trademark Office (USPTO). The required fee has been paid and the patent is expected to be formally issued in Q1 2026. The patent family claims priority from 30 January 2015 and will be in force until 2036.